Haemophilia A and B are rare congenital, recessive X-linked disorders caused by lack or deficiency of clotting factor VIII (FVIII) or IX (FIX), respectively. The severity of the disease depends on the reduction of levels of FVIII or FIX, which are determined by the type of the causative mutation in the genes encoding the factors (F8 and F9, respectively). The hallmark clinical characteristic, especially in untreated severe forms, is bleeding (spontaneous or after trauma) into major joints such as ankles, knees and elbows, which can result in the development of arthropathy. Intracranial bleeds and bleeds into internal organs may be life-threatening. The median life expectancy was ~30 years until the 1960s, but improved understanding of the disorder and development of efficacious therapy based on prophylactic replacement of the missing factor has caused a paradigm shift, and today individuals with haemophilia can look forward to a virtually normal life expectancy and quality of life. Nevertheless, the potential development of inhibitory antibodies to infused factor is still a major hurdle to overcome in a substantial proportion of patients. Finally, gene therapy for both types of haemophilia has progressed remarkably and could soon become a reality.
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Berntorp, E. & Shapiro, A. D. Modern haemophilia care. Lancet 379, 1447–1456 (2012). This is an easily accesible review of the fundamentals of modern haemophilia care. Still relevant despite publication year.
Biggs, R. & Macfarlane, R. G. Haemophilia and related conditions: a survey of 187 cases. Br. J. Haematol. 4, 1–27 (1958).
White, G. C. 2nd et al. Definitions in hemophilia. Thromb. Haemost. 85, 560 (2001).
Fischer, K. et al. Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry. Haemophilia 20, e280–e286 (2014).
WFH. Report on the Annual Global Survey 2019 http://www1.wfh.org/publications/files/pdf-1806.pdf (2020). The WFH Global Survey gives a good and up to date picture of demographics for haemophilia and other rare bleeding disorders worldwide.
van den Berg, H. M. et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood 134, 317–320 (2019).
Oldenburg, J. & Levy, G. G. Emicizumab prophylaxis in hemophilia a with inhibitors. N. Engl. J. Med. 377, 2194–2195 (2017).
Mahlangu, J. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N. Engl. J. Med. 379, 811–822 (2018).
Gollomp, K. L., Doshi, B. S. & Arruda, V. R. Gene therapy for hemophilia: progress to date and challenges moving forward. Transfus. Apher. Sci. 58, 602–612 (2019). This paper is a must-read for those who want to learn the story of gene therapy in haemophilia.
Nathwani, A. C. Gene therapy for hemophilia. Hematol. Am. Soc. Hematol. Educ. Program. 2019, 1–8 (2019).
Larsson, S. A. Life expectancy of Swedish haemophiliacs, 1831-1980. Br. J. Haematol. 59, 593–602 (1985).
Mauser-Bunschoten, E. P., Fransen Van De Putte, D. E. & Schutgens, R. E. Co-morbidity in the ageing haemophilia patient: the down side of increased life expectancy. Haemophilia 15, 853–863 (2009).
Stonebraker, J. S., Bolton-Maggs, P. H., Soucie, J. M., Walker, I. & Brooker, M. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 16, 20–32 (2010).
Hassan, S. et al. Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. J. Thromb. Haemost. 19, 645–653 (2021).
Colvin, B. T. et al. European principles of haemophilia care. Haemophilia 14, 361–374 (2008). This article discusses important principles that should be followed by all haemophilia centres.
UKHCDO. Annual Report. Bleeding disorder statistics for 2014/2015. http://www.ukhcdo.org/wp-content/uploads/2019/04/2015_UKHCDO_Annual_Report_2014_15_Data.pdf (2015).
EAHAD. EUHASS newest annual reports. https://eahad.org/euhass-newest-annual-report-published/ (2018).
Stonebraker, J. S., Bolton-Maggs, P. H., Michael Soucie, J., Walker, I. & Brooker, M. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 18, e91–e94 (2012).
MacLean, P. E., Fijnvandraat, K., Beijlevelt, M. & Peters, M. The impact of unaware carriership on the clinical presentation of haemophilia. Haemophilia 10, 560–564 (2004).
Biggs, R. et al. Christmas disease: a condition previously mistaken for haemophilia. Br. Med. J. 2, 1378–1382 (1952).
Hoffman, M. & Monroe, D. M. III A cell-based model of hemostasis. Thromb. Haemost. 85, 958–965 (2001).
Vehar, G. A. et al. Structure of human factor VIII. Nature 312, 337–342 (1984). This paper really paves the road for molecular biology techniques in haemophilia, such as recombinant FVIII products and gene therapy.
Mannucci, P. M. & Tuddenham, E. G. The hemophilias—from royal genes to gene therapy. N. Engl. J. Med. 344, 1773–1779 (2001). This is a frequently cited paper on haemophilia history up to contemporary issues.
Rogaev, E. I., Grigorenko, A. P., Faskhutdinova, G., Kittler, E. L. & Moliaka, Y. K. Genotype analysis identifies the cause of the “royal disease”. Science 326, 817 (2009).
Acquila, M., Caprino, D., Bicocchi, P., Mori, P. G. & Tagliaferri, A. R. A skewed lyonization phenomenon as cause of hemophilia A in a female patient. Blood 85, 599–600 (1995).
Makris, M. et al. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J. Thromb. Haemost. 16, 2530–2533 (2018).
Graw, J., B. H., Oldenburg, J., Schramm, W. & Schwaab, R. in 30th Hemophilia Symposium (eds Schramm, W. & Scharrer, I.) (Springer, 2001).
Oldenburg, J. et al. De novo factor VIII gene intron 22 inversion in a female carrier presents as a somatic mosaicism. Blood 96, 2905–2906 (2000).
Collins, P. W. et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood 124, 3389–3397 (2014).
Peyvandi, F. et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N. Engl. J. Med. 374, 2054–2064 (2016).
Astermark, J. et al. The polygenic nature of inhibitors in hemophilia a: results from the Hemophilia Inhibitor Genetics Study (HIGS) combined cohort. Blood 121, 1446–1454 (2013).
Astermark, J. et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108, 3739–3745 (2006).
Pavlova, A. et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J. Thromb. Haemost. 7, 2006–2015 (2009).
Hart, D. P. et al. Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A. Haematologica 104, 599–608 (2019).
Eckhardt, C. L. et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 122, 1954–1962 (2013).
Kannicht, C. et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb. Res. 131, 78–88 (2013).
Hansson, K. & Stenflo, J. Post-translational modifications in proteins involved in blood coagulation. J. Thromb. Haemost. 3, 2633–2648 (2005).
Everett, L. A., Cleuren, A. C., Khoriaty, R. N. & Ginsburg, D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 123, 3697–3705 (2014).
Fahs, S. A., Hille, M. T., Shi, Q., Weiler, H. & Montgomery, R. R. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123, 3706–3713 (2014).
Shahani, T. et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J. Thromb. Haemost. 12, 36–42 (2014).
Fay, P. J., Haidaris, P. J. & Smudzin, T. M. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J. Biol. Chem. 266, 8957–8962 (1991).
Newell, J. L. & Fay, P. J. Proteolysis at Arg740 facilitates subsequent bond cleavages during thrombin-catalyzed activation of factor VIII. J. Biol. Chem. 282, 25367–25375 (2007).
Gilbert, G. E., Furie, B. C. & Furie, B. Binding of human factor VIII to phospholipid vesicles. J. Biol. Chem. 265, 815–822 (1990).
Gilbert, G. E., Novakovic, V. A., Shi, J., Rasmussen, J. & Pipe, S. W. Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine. Blood 126, 1237–1244 (2015).
Mann, K. G., Jenny, R. J. & Krishnaswamy, S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu. Rev. Biochem. 57, 915–956 (1988).
Khan, A. R. & James, M. N. Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes. Protein Sci. 7, 815–836 (1998).
Mertens, K., Cupers, R., Van Wijngaarden, A. & Bertina, R. M. Binding of human blood-coagulation Factors IXa and X to phospholipid membranes. Biochem. J. 223, 599–605 (1984).
Spaargaren, J. et al. Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. Biochem. J. 310, 539–545 (1995).
Choo, K. H., Gould, K. G., Rees, D. J. & Brownlee, G. G. Molecular cloning of the gene for human anti-haemophilic factor IX. Nature 299, 178–180 (1982).
Male, C. et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 106, 123–129 (2021).
Crossley, M. et al. Recovery from hemophilia B Leyden: an androgen-responsive element in the factor IX promoter. Science 257, 377–379 (1992).
Morgan, G. E. et al. Further evidence for the importance of an androgen response element in the factor IX promoter. Br. J. Haematol. 98, 79–85 (1997).
Simioni, P. et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N. Engl. J. Med. 361, 1671–1675 (2009).
Samelson-Jones, B. J., Finn, J. D., George, L. A., Camire, R. M. & Arruda, V. R. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight 5, e128683 (2019).
Cooley, B. et al. Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood 128, 286–292 (2016).
Vadivel, K. & Bajaj, S. P. Structural biology of factor VIIa/tissue factor initiated coagulation. Front. Biosci. 17, 2476–2494 (2012).
Geng, Y. et al. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J. Biol. Chem. 287, 38200–38209 (2012).
Geng, Y. et al. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa. JTH 11, 1374–1384 (2013).
Monahan, P. E. Velander, W. H. & Bajaj, S. P. in Handbook of Proteolytic Enzymes 3rd edn Ch. 640 (eds Rawlings, S. D. & Salvesen, G.) 2898–2905 (Academic Press, 2013).
Hooiveld, M. et al. Blood-induced joint damage: longterm effects in vitro and in vivo. J. Rheumatol. 30, 339–344 (2003).
van Vulpen, L. F. et al. IL-1beta, in contrast to TNFalpha, is pivotal in blood-induced cartilage damage and is a potential target for therapy. Blood 126, 2239–2246 (2015).
Hooiveld, M. J. et al. Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy. Arthritis Rheum. 50, 2024–2031 (2004).
Roosendaal, G. et al. Blood-induced joint damage: a human in vitro study. Arthritis Rheum. 42, 1025–1032 (1999).
Dunn, A. Pathophysiology, diagnosis and prevention of arthropathy in patients with haemophilia. Haemophilia 17, 571–578 (2011).
Rodriguez-Merchan, E. C. Musculo-skeletal manifestations of haemophilia. Blood Rev. 30, 401–409 (2016). This is a comprehensive paper on the main musculo-skeletal sequelae of haemophilic bleedings.
Stephensen, D. et al. Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia 15, 1210–1214 (2009).
Scott, M. J. et al. Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia 25, 205–212 (2019).
Drake, T. A., Morrissey, J. H. & Edgington, T. S. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am. J. Pathol. 134, 1087–1097 (1989).
Cooke, E. J. et al. Vascular permeability and remodelling coincide with inflammatory and reparative processes after joint bleeding in factor VIII-deficient mice. Thromb. Haemost. 118, 1036–1047 (2018).
Hakobyan, N., Kazarian, T., Jabbar, A. A., Jabbar, K. J. & Valentino, L. A. Pathobiology of hemophilic synovitis I: overexpression of mdm2 oncogene. Blood 104, 2060–2064 (2004).
Hooiveld, M. et al. Short-term exposure of cartilage to blood results in chondrocyte apoptosis. Am. J. Pathol. 162, 943–951 (2003).
Pulles, A. E. et al. Proteoglycan synthesis rate as a novel method to measure blood-induced cartilage degeneration in non-haemophilic and haemophilic rats. Haemophilia https://doi.org/10.1111/hae.13969 (2020).
Christensen, K. R. et al. Rapid inflammation and early degeneration of bone and cartilage revealed in a time-course study of induced haemarthrosis in haemophilic rats. Rheumatology 58, 588–599 (2019).
Jansen, N. W., Roosendaal, G., Bijlsma, J. W., Degroot, J. & Lafeber, F. P. Exposure of human cartilage tissue to low concentrations of blood for a short period of time leads to prolonged cartilage damage: an in vitro study. Arthritis Rheum. 56, 199–207 (2007).
Ovlisen, K., Kristensen, A. T., Jensen, A. L. & Tranholm, M. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia 15, 802–810 (2009).
Roosendaal, G. et al. Iron deposits and catabolic properties of synovial tissue from patients with haemophilia. J. Bone Jt. Surg. Br. 80, 540–545 (1998).
Hooiveld, M. J., Roosendaal, G., van den Berg, H. M., Bijlsma, J. W. & Lafeber, F. P. Haemoglobin-derived iron-dependent hydroxyl radical formation in blood-induced joint damage: an in vitro study. Rheumatology 42, 784–790 (2003).
Roosendaal, G. et al. Blood-induced joint damage: a canine in vivo study. Arthritis Rheum. 42, 1033–1039 (1999).
Mannucci, P. M., Coppola, R., Lombardi, R., Papa, M. & de Biasi, R. Direct proof of extreme lyonization as a cause of low factor VIII levels in females. Thromb. Haemost. 39, 544–545 (1978).
Renault, N. K. et al. Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females. Eur. J. Hum. Genet. 15, 628–637 (2007).
Antonarakis, S. E. et al. Hemophilia A. Detection of molecular defects and of carriers by DNA analysis. N. Engl. J. Med. 313, 842–848 (1985).
Den Uijl, I. E. et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia 17, 849–853 (2011).
Srivastava, A. et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia https://doi.org/10.1111/hae.14046 (2020). These are newly issued haemophilia guidelines authored by a number of international experts.
Ljung, R. C. Intracranial haemorrhage in haemophilia A and B. Br. J. Haematol. 140, 378–384 (2008).
Davies, J. & Kadir, R. A. Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta-analysis of the literature. Haemophilia 22, 32–38 (2016).
Marlar, R. A., Strandberg, K., Shima, M. & Adcock, D. M. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B. Eur. J. Haematol. 104, 3–14 (2020).
Kitchen, S. et al. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays. J. Thromb. Haemost. 14, 757–764 (2016).
Pavlova, A., Delev, D., Pezeshkpoor, B., Muller, J. & Oldenburg, J. Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays. Thromb. Haemost. 111, 851–861 (2014).
Cid, A. R. et al. One-stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype. Haemophilia 14, 1049–1054 (2008).
Trossaert, M. et al. Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one-stage and chromogenic factor VIII activity. J. Thromb. Haemost. 9, 524–530 (2011).
Laurie, A. D. et al. Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches. J. Thromb. Haemost. 8, 783–789 (2010).
Ljung, R. C. Prenatal diagnosis of haemophilia. Haemophilia 5, 84–87 (1999).
Cutler, J., Chappell, L. C., Kyle, P. & Madan, B. Third trimester amniocentesis for diagnosis of inherited bleeding disorders prior to delivery. Haemophilia 19, 904–907 (2013).
Tabor, A. & Alfirevic, Z. Update on procedure-related risks for prenatal diagnosis techniques. Fetal Diagn. Ther. 27, 1–7 (2010).
Bustamante-Aragones, A. et al. Foetal sex determination in maternal blood from the seventh week of gestation and its role in diagnosing haemophilia in the foetuses of female carriers. Haemophilia 14, 593–598 (2008).
Ljung, R. C. & Sjorin, E. Origin of mutation in sporadic cases of haemophilia A. Br. J. Haematol. 106, 870–874 (1999).
Leuer, M. et al. Somatic mosaicism in hemophilia A: a fairly common event. Am. J. Hum. Genet. 69, 75–87 (2001).
Edwards, J. H. Familiarity, recessivity and germline mosaicism. Ann. Hum. Genet. 53, 33–47 (1989).
Gupta, S. & Shapiro, A. D. Optimizing bleed prevention throughout the lifespan: womb to tomb. Haemophilia 24 (Suppl. 6), 76–86 (2018).
Shapiro, A. D., Mitchell, I. S. & Nasr, S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J. Thromb. Haemost. 16, 2362–2374 (2018).
Hoots, W. K. & Shapiro, A. D. Treatment of bleeding and perioperative management in hemophilia A and B. UpToDate, https://www.uptodate.com/contents/treatment-of-bleeding-and-perioperative-management-in-hemophilia-a-and-b (2021).
Pai, M. et al. NHF-McMaster guideline on care models for haemophilia management. Haemophilia 22 (Suppl. 3), 6–16 (2016).
Pipe, S. W. & Kessler, C. M. Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care. Haemophilia 22 (Suppl. 3), 3–5 (2016).
Soucie, J. M. et al. Mortality among males with hemophilia: relations with source of medical care. Blood 96, 437–442 (2000).
Soucie, J. M. et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 7, 198–206 (2001).
Schutgens, R. E. G., Voskuil, M. & Mauser-Bunschoten, E. P. Management of cardiovascular disease in aging persons with haemophilia. Hamostaseologie 37, 196–201 (2017).
Mannucci, P. M. & Iacobelli, M. Progress in the contemporary management of hemophilia: the new issue of patient aging. Eur. J. Intern. Med. 43, 16–21 (2017).
Hollingdrake, O. et al. Haemophilia and age-related comorbidities: do men with haemophilia consult a general practitioner for men’s preventative health checks. Haemophilia 22, e335–e337 (2016).
Boccalandro, E. et al. Ageing successfully with haemophilia: a multidisciplinary programme. Haemophilia 24, 57–62 (2018).
World Federation of Hemophilia. Guidelines for the Management of Hemophilia. https://www1.wfh.org/publication/files/pdf-1472.pdf (2012).
Manco-Johnson, M. J. et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N. Engl. J. Med. 357, 535–544 (2007).
Manco-Johnson, M. J., Soucie, J. M. & Gill, J. C. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood 129, 2368–2374 (2017).
Collins, P. W. et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J. Thromb. Haemost. 7, 413–420 (2009).
Skinner, M. W. WFH: closing the global gap–achieving optimal care. Haemophilia 18 (Suppl. 4), 1–12 (2012).
Fischer, K. et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia 8, 753–760 (2002).
Oldenburg, J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 125, 2038–2044 (2015).
Krämer, L. Retrospektive Studie zu den Auswirkungen der Langzeitprophylaxe mit Faktor VIII-Konzentrat bei Patienten mit schwerer Hämophilie A auf den Gelänkstatus von Kniegelenk, oberen Sprunggelenk un Ellenbogengelenk (Universität Bonn, 2013).
den Uijl, I. E. et al. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 17, 41–44 (2011).
Fischer, K. Optimizing efficacy of factor VIII prophylaxis for severe haemophilia A. Haemophilia 17, 9–15 (2011).
Lundin, B., Ljung, R. & Pettersson, H., European Paediatric Network for Haemophilia Management (PEDNET). MRI scores of ankle joints in children with haemophilia-comparison with clinical data. Haemophilia 11, 116–122 (2005).
De la Corte-Rodriguez, H., Rodriguez-Merchan, E. C. & Jimenez-Yuste, V. Point-of-care ultrasonography in orthopedic management of hemophilia: multiple uses of an effective tool. HSS J. 14, 307–313 (2018).
National Hemophilia Foundation. MASAC Recommendations Regarding Doses of Clotting Factor Concentrate in the Home. Document #242. https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-Regarding-Doses-of-Clotting-Factor-Concentrate-in-the-Home (2016).
Kitchen, S., Kershaw, G. & Tiefenbacher, S. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues. Haemophilia 22 (Suppl. 5), 72–77 (2016).
Rodriguez-Merchan, E. C. Serological biomarkers in hemophilic arthropathy: can they be used to monitor bleeding and ongoing progression of blood-induced joint disease in patients with hemophilia? Blood Rev. 41, 100642 (2020).
Mancuso, M. E. & Santagostino, E. Outcome of clinical trials with new extended half-life FVIII/IX concentrates. J. Clin. Med. 6, 39 (2017).
Ar, M. C., Balkan, C. & Kavakli, K. Extended half-life coagulation factors: a new era in the management of hemophilia patients. Turk. J. Haematol. 36, 141–154 (2019).
Bjorkman, S. Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A. Haemophilia 16, 597–605 (2010).
Meeks, S. L. & Batsuli, G. Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches. Hematol. Am. Soc. Hematol. Educ. Program. 2016, 657–662 (2016).
Miller, C. H. et al. F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race/ethnicity. Haemophilia 18, 375–382 (2012).
European Medicines Agency. Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes. EMA/603417/2017. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2017/09/WC500234822.pdf (2017).
Miller, C. H. et al. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J. Thromb. Haemost. 11, 1300–1309 (2013).
van den Berg, H. M. Different impact of factor VIII products on inhibitor development? Thromb. J. 14, 31 (2016).
Soucie, J. M. et al. A study of prospective surveillance for inhibitors among persons with haemophilia in the United States. Haemophilia 20, 230–237 (2014).
Hay, C. R. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 4, 558–563 (1998).
Giuffrida, A. C. et al. Inhibitors in mild/moderate haemophilia A: two case reports and a literature review. Blood Transfus. 6, 163–168 (2008).
National Hemophilia Foundation. MASAC Recommendations on Standardized Testing and Surveillance for Inhibitors in Patients with Hemophilia A and B. Document #236, https://www.hemophilia.org/Researchers-Healthcare-Providers/Medical-and-Scientific-Advisory-Council-MASAC/MASAC-Recommendations/MASAC-Recommendations-on-Standardized-Testing-and-Surveillance-for-Inhibitors-in-Patients-with-Hemophilia-A-and-B (2015).
Konkle, B. A. et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J. Thromb. Haemost. 5, 1904–1913 (2007).
Antunes, S. V. et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia 20, 65–72 (2014).
Wang, M. et al. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding. Haemophilia 23, 832–843 (2017).
Nakatomi, Y. et al. Combining FVIIa and FX into a mixture which imparts a unique thrombin generation potential to hemophilic plasma: an in vitro assessment of FVIIa/FX mixture as an alternative bypassing agent. Thromb. Res. 125, 457–463 (2010).
Rocino, A., Franchini, M. & Coppola, A. Treatment and prevention of bleeds in haemophilia patients with inhibitors to factor VIII/IX. J. Clin. Med. 6, 46 (2017).
Tagariello, G. et al. High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance. J. Hematol. Oncol. 6, 63 (2013).
Earnshaw, S. R., Graham, C. N., McDade, C. L., Spears, J. B. & Kessler, C. M. Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia 21, 310–319 (2015).
Holstein, K. et al. Current view and outcome of ITI therapy - a change over time? Thromb. Res. 148, 38–44 (2016).
Benson, G. et al. Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice. Eur. J. Haematol. 88, 371–379 (2012).
Valentino, L. A. et al. US Guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia 21, 559–567 (2015).
Nakar, C. et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia 21, 365–373 (2015).
Tengborn, L. et al. Anaphylactoid reactions and nephrotic syndrome–a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers. Haemophilia 4, 854–859 (1998).
Franchini, M. & Mannucci, P. M. Inhibitor eradication with rituximab in haemophilia: where do we stand? Br. J. Haematol. 165, 600–608 (2014).
Ragni, M. V. Novel alternate hemostatic agents for patients with inhibitors: beyond bypass therapy. Hematology 2017, 605–609 (2017).
Pasi, K. J. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N. Engl. J. Med. 377, 819–828 (2017).
Bhat, V., von Drygalski, A., Gale, A. J., Griffin, J. H. & Mosnier, L. O. Improved coagulation and hemostasis in hemophilia with inhibitors by combinations of (super)factor Va and factor VIIa. Thromb. Haemost. 115, 551–561 (2016).
Arkin, S. et al. Escalating single doses of PF-05230907 (recombinant factor Xa variant FXaI16L) are safe and demonstrate hemostatic pharmacology in healthy volunteers [abstract]. Blood 128, 3781–3781 (2016).
Polderdijk, S. G. I., Baglin, T. P. & Huntington, J. A. Targeting activated protein C to treat hemophilia. Curr. Opin. Hematol. 24, 446–452 (2017).
Peterson, J. A., Maroney, S. A. & Mast, A. E. Targeting TFPI for hemophilia treatment. Thromb. Res. 141, S28–S30 (2016).
Rodriguez-Merchan, E. C. & Valentino, L. A. Emicizumab: review of the literature and critical appraisal. Haemophilia 25, 11–20 (2019).
U.S. Food and Drug Administration. FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors. fda.gov https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm585650.htm (2017)
Genentech. Hemlibra [Package Insert], https://www.gene.com/download/pdf/hemlibra_prescribing.pdf (2018).
Oldenburg, J. et al. Emicizumab prophylaxis in hemophilia a with inhibitors. N. Engl. J. Med. 377, 809–818 (2017).
Hartmann, R., Feenstra, T., Valentino, L., Dockal, M. & Scheiflinger, F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J. Thromb. Haemost. 16, 1580–1591 (2018).
National Hemophilia Foundation. Recommendation on the Use and Management of Emicizumab-KXWH (Hemlibra®) for Hemophilia A with and without Inhibitors. MASAC document 258, https://www.hemophilia.org/sites/default/files/document/files/258_emicizumab.pdf (2020).
Young, G. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2, 2780–2782 (2018).
Le Quellec, S. & Negrier, C. Emicizumab should be prescribed independent of immune tolerance induction. Blood Adv. 2, 2783–2786 (2018).
Santagostino, E., Young, G., Escuriola Ettingshausen, C., Jimenez-Yuste, V. & Carcao, M. Inhibitors: a need for eradication? Acta Haematol. 141, 151–155 (2019).
Ljung, R. et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur. J. Haematol. 102, 111–122 (2019).
Batsuli, G., Zimowski, K. L., Tickle, K., Meeks, S. L. & Sidonio, R. F. Jr Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 25, 789–796 (2019).
George, L. A. Hemophilia gene therapy comes of age. Blood Adv. 1, 2591–2599 (2017).
George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med. 377, 2215–2227 (2017).
Pasi, K. J. et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N. Engl. J. Med. 382, 29–40 (2020).
George, L. et al. Phase I/II trial of SPK-8011: stable and durable FVIII expression for >2 years with significant ABR improvements in initial dose cohorts following AAV-mediated FVIII gene transfer for hemophilia A [abstract]. Res. Pract. Thromb. Haemost. 4, OC 03.5 (2020).
Samelson-Jones, B. J. et al. Evolutionary insights into coagulation factor IX Padua and other high-specific-activity variants. Blood Adv. 5, 1324–1332 (2021).
Nathwani, A. C. R. U., Tuddenham, E., Chowdary, P., McIntosh, J. & Riddell, A. et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing “empty viral particles” on safety and efficacy of gene transfer. Blood 132, 491 (2018).
Manno, C. S. et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342–347 (2006).
Mingozzi, F. et al. CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419–422 (2007).
Hoots, W. K. Emergency Care Issues in Hemophilia. Treatment of Hemophilia series 43, http://www1.wfh.org/publication/files/pdf-1196.pdf (2007).
Donaldson, J. & Goddard, N. Compartment syndrome in patients with haemophilia. J. Orthop. 12, 237–241 (2015).
Caviglia, H., Landro, M., Galatro, G., Candela, M. & Neme, D. Pseudotumors of the limbs in patients with hemophilia. J. Blood Disord. 2, 1026 (2015).
van Vulpen, L. F. D., Mastbergen, S. C., Lafeber, F. & Schutgens, R. E. G. Differential effects of bleeds on the development of arthropathy - basic and applied issues. Haemophilia 23, 521–527 (2017).
Simpson, M. L. & Valentino, L. A. Management of joint bleeding in hemophilia. Expert. Rev. Hematol. 5, 459–468 (2012).
Rodriguez-Merchan, E. C. Radiosynovectomy in haemophilia. Blood Rev. 35, 1–6 (2019).
Rodriguez-Merchan, E. C. & Valentino, L. A. Safety of radiation exposure after radiosynovectomy in paediatric patients with haemophilia. Haemophilia 21, 411–418 (2015).
Rodriguez-Merchan, E. C. The role of orthopaedic surgery in haemophilia: current rationale, indications and results. EFORT Open. Rev. 4, 165–173 (2019).
Manners, P. J. et al. Joint aspiration for acute hemarthrosis in children receiving factor VIII prophylaxis for severe hemophilia: 11-year safety data. J. Rheumatol. 42, 885–890 (2015).
De la Corte-Rodriguez, H. et al. Accelerating recovery from acute hemarthrosis in patients with hemophilia: the role of joint aspiration. Blood Coagul. Fibrinolysis 30, 111–119 (2019).
Lewandowska, M. et al. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US. Haemophilia 27, 90–99 (2021).
Muller, J. et al. Laboratory monitoring in emicizumab-treated persons with hemophilia A. Thromb. Haemost. 119, 1384–1393 (2019).
Auerswald, G. et al. Pain and pain management in haemophilia. Blood Coagul. Fibrinolysis 27, 845–854 (2016).
Humphries, T. J. & Kessler, C. M. Managing chronic pain in adults with haemophilia: current status and call to action. Haemophilia 21, 41–51 (2015).
Rodriguez-Merchan, E. C. Treatment of musculo-skeletal pain in haemophilia. Blood Rev. 32, 116–121 (2018).
Holstein, K. et al. Pain management in patients with haemophilia: a European survey. Haemophilia 18, 743–752 (2012).
Witkop, M. et al. Assessment of acute and persistent pain management in patients with haemophilia. Haemophilia 17, 612–619 (2011).
Wallny, T. et al. Pain status of patients with severe haemophilic arthropathy. Haemophilia 7, 453–458 (2001).
No Authors listed. Study protocol for the World Health Organization project to develop a Quality of Life assessment instrument (WHOQOL). Qual. Life Res. 2, 153–159 (1993).
Limperg, P. F. et al. Health-related quality of life questionnaires in individuals with haemophilia: a systematic review of their measurement properties. Haemophilia 23, 497–510 (2017).
van Balen, E. et al. Patient-relevant health outcomes for hemophilia care: development of an international standard outcomes set. Res. Pract. Thromb. Haemost. 5, e12488 (2021). Patient-relevant outcomes are important in follow-up of haemophilia treatment. This paper describes a set of important outcomes including QoL, based on a systematic literature review.
van den Berg, H. M. et al. Assessments of outcome in haemophilia - what is the added value of QoL tools? Haemophilia 21, 430–435 (2015).
Carcao, M. et al. Measuring the impact of changing from standard half-life (SHL) to extended half-life (EHL) FVIII prophylaxis on health-related quality of life (HRQoL) in boys with moderate/severe haemophilia A: lessons learned with the CHO-KLAT tool. Haemophilia 26, 73–78 (2020).
Price, V. E. et al. Updating the Canadian Hemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) in the era of extended half-life clotting factor concentrates. Res. Pract. Thromb. Haemost. 5, 403–411 (2021).
Dover, S. et al. Measuring the impact of hemophilia on families: development of the Hemophilia Family Impact Tool (H-FIT). Res. Pract. Thromb. Haemost. 5, e12519 (2021).
Carcao, M. et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 25, 676–684 (2019).
Pierce, G. F. et al. First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries. Haemophilia 24, 229–235 (2018).
Maseide, R. J. et al. Joint health and treatment modalities in Nordic patients with moderate haemophilia A and B - the MoHem study. Haemophilia 26, 891–897 (2020).
Olsson, A., Hellgren, M., Berntorp, E. & Baghaei, F. Association between bleeding tendency and health-related quality of life in carriers of moderate and severe haemophilia. Haemophilia 21, 742–746 (2015).
Chambost, H. & Ljung, R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 11, 92–99 (2005).
Makris, M. et al. EUHASS: The European Haemophilia Safety Surveillance system. Thromb. Res. 127 (Suppl. 2), S22–S25 (2011).
Fischer, K. et al. Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood 122, 1129–1136 (2013).
Collins, P. W. et al. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 17, 2–10 (2011).
Astermark, J. et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br. J. Haematol. 105, 1109–1113 (1999).
Fischer, K. et al. When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. J. Thromb. Haemost. 14, 1105–1109 (2016).
Bjorkman, S. & Collins, P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J. Thromb. Haemost. 11, 180–182 (2013).
Lenting, P. J., Denis, C. V. & Christophe, O. D. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII? Blood 130, 2463–2468 (2017).
Pipe, S. W. et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 6, e295–e305 (2019).
Ferrante, F. I. S., Kunze, M. & Michaels, L. A. Anti-TFPI antibody BAY1093884: early termination of phase II dose escalation study due to thrombosis. Haemophilia 26, 77–78 (2020).
Figueiredo, M. Novo Nordisk pauses 3 clinical trials of concizumab amid safety concerns, Hemophila News Today, https://hemophilianewstoday.com/2020/03/18/novo-nordisk-pauses-three-clinical-trials-of-concizumab-due-to-safety-concerns/ (2020).
Astermark, J. FVIII inhibitors: pathogenesis and avoidance. Blood 125, 2045–2051 (2015).
Young, G. et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134, 2127–2138 (2019).
Astermark, J. et al. The Malmo International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A. Haematologica 90, 924–931 (2005).
Gouw, S. C. et al. Factor VIII products and inhibitor development in severe hemophilia A. N. Engl. J. Med. 368, 231–239 (2013).
Gouw, S. C., van der Bom, J. G. & Marijke van den Berg, H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 109, 4648–4654 (2007).
Brackmann, H. H. & Gormsen, J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 2, 933 (1977).
Astermark, J. Immune tolerance induction in patients with hemophilia A. Thromb. Res. 127 (Suppl. 1), S6–S9 (2011).
Pasi, K. J. et al. Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran - results of the phase 1 inhibitor cohort. J. Thromb. Haemost. https://doi.org/10.1111/jth.15270 (2021).
Blas, Y. D. et al. Phase 1b study to evaluate safety, tolerability, and maximum tolerated dose of PF-05230907 for intracerebral hemorrhage. Stroke 52, 294–298 (2021).
Croteau, S. E., Wang, M. & Wheeler, A. P. 2021 clinical trials update: Innovations in hemophilia therapy. Am. J. Hematol. 96, 128–144 (2021).
Chowdary, P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia. Int. J. Hematol. 111, 42–50 (2020).
Lenting, P. J. Laboratory monitoring of hemophilia A treatments: new challenges. Blood Adv. 4, 2111–2118 (2020).
Martel-Pelletier, J. et al. Osteoarthritis. Nat. Rev. Dis. Prim. 2, 16072 (2016).
WHO. Towards a Common Language for Functioning, Disability and Health: ICF The International Classification of Functioning, Disability and Health, https://cdn.who.int/media/docs/default-source/classification/icf/icfbeginnersguide.pdf?sfvrsn=eead63d3_4 (2002)
Young, N. L. et al. Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT). Haemophilia 10 (Suppl. 1), 34–43 (2004).
von Mackensen, S., Bullinger, M. & Haemo-Qo, L. G. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia 10 (Suppl. 1), 17–25 (2004).
Pollak, E., Muhlan, H., Mackensen, S. V. & Bullinger, M., HAEMO-QOL Group. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia 12, 384–392 (2006).
Manco-Johnson, M., Morrissey-Harding, G., Edelman-Lewis, B., Oster, G. & Larson, P. Development and validation of a measure of disease-specific quality of life in young children with haemophilia. Haemophilia 10, 34–41 (2004).
Mackensen, S. & Gringeri, A. Development and pilot testing of a disease-specific quality of life questionnaire for adult patients with haemophilia (Ham-A-QoL). Blood 104, 2214 (2004).
Rentz, A. et al. Cross-cultural development and psychometric evaluation of a patient-reported health-related quality of life questionnaire for adults with haemophilia. Haemophilia 14, 1023–1034 (2008).
Arranz, P. et al. Development of a new disease-specific quality-of-life questionnaire to adults living with haemophilia. Haemophilia 10, 376–382 (2004).
Remor, E. Development and psychometric testing of the Hemophilia Well-being Index. Int. J. Behav. Med. 20, 609–617 (2013).
Remor, E. Hemolatin-QoL Desarollo de medida especifica para la evaluacónde la calidad de vida en pacientas adultos con hemophilia en America-Latina Terapic. Rev. Interam. de. Psicol.ía/Interam. J. Psychol. 39, 211–220 (2005).
E.B. has received grants and/or research support from Bayer, CSL Behring, Shire and Sobi/Bioverativ and honoraria and/or consultation fees from Bayer, Octapharma and Shire/Takeda. The Van Creveldkliniek has received speaker’s fees from Bayer, Baxter/Shire, Sobi/Biogen, CSL Behring and Novo Nordisk; has performed consultancy for Bayer, Biogen, CSL Behring, Freeline, Novo Nordisk, Roche and Sobi; and has received research support from Bayer, Baxter/Shire, Novo Nordisk, Pfizer and Biogen for work done by K.F. Queen Mary University London has received research grants from Bayer, Octapharma and Takeda for work performed by D.P.H. He or his institution have received speaker or consultancy honoraria from Bayer, BioMarin, Biotest, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Sanofi, Spark Therapeutics, Sobi, Takeda and UniQure. M.E.M. has acted as paid consultant, adviser or speaker for Bayer Healthcare, BioMarin, Catalyst, CSL Behring, Grifols, Kedrion, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Spark Therapeutics and Takeda. D.S. is Chair of EAHAD Physiotherapy Committee, received research grant funding from the National Institute for Health Resarch (NIHR), Novo Nordisk, Pfizer, Roche, Sobi and acted as paid adviser or speaker for Bayer, Pfizer, Sobi, Roche and Takeda. V.B. is Chair of the International Prophylaxis Study Group (the IPSG), which is funded by grants from Bayer Healthcare, Bioverativ (now Sanofi/Genzyme), Novo Nordisk, Pfizer, Shire (now Takeda) and Spark Therapeutics to the Hospital for Sick Children Foundation, Toronto, Canada. He has received fees for participation in education events and advisory boards sponsored by Amgen, Bayer Healthcare, Novo Nordisk, Pfizer, Roche and Shire (now Takeda), and for participation in data safety monitoring boards for Octapharma and Takeda. He is recipient of investigator-initiated grants from Bayer Healthcare, Bioverativ (now Sanofi/Genzyme) and Shire (now Takeda). A.D.S. has served as consultant for Genentech, Roche, Novo Nordisk, BioMarin, Bioveritiv, Sanofi, ProMetic Bio Sciences, Kedrion, Sigilon and Takeda. She has received research funding from the above plus Agios, OPKO, Global Bio Therapeutics, Sangamo, Sigilon, Octapharma and Novartis.
Peer review information
Nature Reviews Disease Primers thanks C. Hermans, K. Kavakli and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
EAHAD F8 variants database: https://f8-db.eahad.org
EAHAD F9 variants database: https://f9-db.eahad.org
About this article
Cite this article
Berntorp, E., Fischer, K., Hart, D.P. et al. Haemophilia. Nat Rev Dis Primers 7, 45 (2021). https://doi.org/10.1038/s41572-021-00278-x